Lancaster et al., "Drug Delivery to the Colon: Polymer Susceptibility to Degradation by Colon Contents", Polymer. Prepr. 30:480-1 (1989). |
Rubinstein, A., Biophar. & Drug Disposition 11:465-475 (1990). |
Levine, D. S. et al., Gastroenterology 92:1037-1044 (1987). |
Rasmussen, S. N. et al., Gastroenterology 83:1062-1070 (1982). |
Mardini, H. A. et al., Gut 28:1084-1089 (1987). |
Fairbairn, J. W., J. Pharm. Pharmacol. 1:683-694 (1949). |
Hardcastle, J. D. et al., Gut 11:1038-1042 (1970). |
Cummings, J. H., Gut 15:758-766 (1974). |
Moreto, M. et al., Arzneim-Forsch./Drug Res. 29:1561-1564 (1979). |
Gullikson, G. W. et al., Pharmacology of Intestinal Permeation II, Csaky, T. Z. (ed.), Springer-Verlag, Heidelberg, pp. 419-459 (1984). |
Simpkins, J. W. et al., J. Pharmacol. Exp. Ther. 244:195-205 (1988). |
Klotz, U., Clin. Pharmacokin. 10:285-302 (1985). |
Willoughby, C. P. et al., Gut 23:1081-1087 (1982). |
Bartalsky, A., Lancet 1:960 (1982). |
Brown, J. P. et al., J. Med. Chem. 26:1300-1307 (1983). |
Cummings, J. H. et al., Am. J. Clin. Nutr. 45:1243-1255 (1987). |
Friend, D. R. et al., J. Med. Chem. 28:51-57 (1985). |
Saffran, M. et al., Science 233:1081-1084 (1986). |
Saffran, M. et al., J. Pharm. Sci. 77:33-38 (1988). |
Saffran M. et al., Diabetes 38S:81A (1989). |
Mirelman, D. et al., J. Infect. Dis. 159:303-309 (1989). |
Salyers, A. A., Amer. J. Cli. Nutr. 32:158-163 (1979). |
Salyers, A. A. et al., J. Bacteriol. 143:772-780 (1980). |
Friend, D. R. et al., J. Med. Chem. 27:261-266 (1984). |
Rachmilewitz, D., Br. Med. J. 298:82-86 (1989). |
Supplementary European Search Report to accompany European Application No. 91 91 0743.3, completed Aug. 11, 1993. |
Gassmann, B. et al., "Pharmaceutical Composition with Delayed Activity Release", Chemical Abstracts 103(22), Abstract No. 183574c (Jul. 8, 1985). |
Lancaster, C. M. et al., Drug Delivery to the Colon: Polymer Susceptibility to Degradation by Colon Contents, Chemical Abstracts 110(22), Abstract No. 199047p (Jan. 2, 1989). |
Bartalsky, A., Salicylazobenzoic Acid In Ulcerative Colitis, Lancet:960 (Apr. 24, 1982). |
Brown, J. P. et al., A Polymeric Drug for Treatment of Inflammatory Bowel Disease, J. Med. Chem. 26:1300-1307 (1983). |
Cummings, J. H. et al., Fermentation in the human large intestine and the available substrates, Am. J. Clin. Nutr. 45:1243-1255 (1987). |
Cummings, J. H., Progress Report: Laxative Abuse, Gut 15:758-766 (1974). |
Fairbairn, J. W., The Active Constituents Of The Vegetable Purgatives Containing Anthracene Derivatives, J. Pharm. Pharmacol. 1:683-694 (1949). |
Friend, D. R. et al., A Colon-Specific Drug-Delivery System Based on Drug Glycosides and the Glycosidases of Colonic Bacteria, J. Med. Chem. 27:261-266 (1984). |
Friend, D. R. et al., Drug Glycosides: Potential Prodrugs for Colon-Specific Drug Delivery, J. Med. Chem. 28:51-57 (1985). |
Gassman, B. et al., Pharmaceutical Composition with Delayed Activity Release, Chemical Abstracts 103(22), Abstract No. 183574c (Jul. 8, 1985). |
Gullikson, G. W. et al., Mechanisms of Action of Laxative Drugs, in Csaky, T. Z., ed., Pharmacology of Intestinal Permeation II, Springer-Verlag, Heidelberg, pp. 419-459 (1984). |
Hardcastle, J. D. et al., The Action of Sennosides and Related Compounds on Human Colon and Rectum, Gut 11:1038-1042 (1970). |
Klotz, U., Clinical Pharmacokinetics of Sulphasalazine, Its Metabolites and Other Prodrugs of 5-Aminosalicyclic Acid, Clin. Pharmacokinetics 10:285-302 (1985). |
Lancaster, C. M. et al., Drug Delivery to the Colon: Polymer Susceptibility to Degradation by Colon Contents, Chemical Abstracts 110(22), Abstract No. 199047p (Jan. 2, 1989). |
Levine, D. S. et al., Coating of Oral Beclomethasone Dipropionate Capsules With Cellulose Acetate Phthalate Enhances Delivery of Topically Active Antiinflammatory Drug to the Terminal Ileum, Gastroneterol. 92:1037-1044 (1987). |
Mardini, H. A. et al., Effect of Polymer Coating on Faecal Recovery of Ingested 5-Amino Salicylic Acid In Patients with Ulcerative Colitis, Gut 28:1084-1089 (1987). |
Mirelman, D. et al., Effects of Covalently Bound Silica-Nitroimidazole Drug Particles on Entamoeba histolytica, J. Infect. Dis. 159(2):303-309 (1989). |
Moreto, M. et al., 3,3-Bis-(4-hydroxyphenyl)-7-methyl-2-indolinone (BHMI), the Active Metabolite of the Laxative Sulisatin, Arnzeim. -Forsch./Drug Res. 29:1561-1564 (1979). |
Rachmilewitz, D., Coated Mesalazine (5-aminosalicyclic acid) Versus Sulphasalazine in the Treatment of Active Ulcerative Colitis: A Randomised Trial, Brit. Med. J. 298:82-86 (1989). |
Rasmussen, S. N. et al., 5-Aminosalicyclic Acid in a Slow-Release Preparation: Bioavailability, Plasma Level, and Excretion in Humans, Gastroenterol. 83:1062-1070 (1982). |
Rubinstein, A., Microbially Controlled Drug Delivery To The Colon, Biopharm. Drug Dispos. 11:465-475 (1990). |
Saffran, M. et al., A New Approach to the Oral Administration of Insulin and Other Peptide Drugs, Science 233:1081-1084 (1986). |
Saffran, M. et al., Oral Insulin in Diabetic Dogs, Diabetes 38S:81A, Abstract No. 324 (1989). |
Saffran, M. et al., Vasopressin: A Model for the Study of Effects of Additives on the Oral and Rectal Administration of Peptide Drugs, J. Pharm. Sci. 77(1):33-38 (1988). |
Salyers, A. A., Energy Sources of Major Intestinal Fermentative Anaerobes, Am. J. Clin. Nutr. 32:158-163 (1979). |
Salyers, A. A. et al., Cellular Location of Enzymes Involved in Chondroitin Sulfate Breakdown by Bacteroides thetaiotaomicron, J. Bacteriol. 143(2):772-780 (1980). |
Simpkins, J. W. et al., Evidence for the Delivery of Narcotic Antagonists to the Colon as their Glucuronide Conjugates, J. Pharmacol. Exper. Therap. 244(1):195-205 (1988). |
Willoughby, C. P. et al., Distribution and Metabolism in Healthy Volunteers of Disodium Azodisalicylate, a Potential Therapeutic Agent for Ulcerative Colitis, Gut 23:1081-1087 (1982). |